Rebecca Chambers has been appointed Chief Financial Officer of Outset Medical.
Over the course of her career at Illumina, Rebecca Chambers led numerous financial functions including treasury, clinical financial planning and analysis and investor relations (IR). Prior to Illumina, she led IR and corporate communications at Myriad Genetics, a molecular diagnostics company in Salt Lake City, Utah, as well as various roles at Life Technologies, now part of Thermo Fisher Scientific, Bank of America Merrill Lynch, and Millennium Pharmaceuticals, now Takeda Pharmaceuticals.
“Rebecca’s deep capital markets expertise and growth-company track record is ideally suited to our stage of commercial expansion,” said Leslie Trigg, Outset’s Chief Executive Officer. “We recognized in Rebecca a best-in-class ability to build a strong financial foundation and effective, transparent relationships with the investment community. We are thrilled to welcome her to the leadership team.”
“I am honored to be a part of Outset at this time in its growth trajectory. It is a rare opportunity to join a team passionate about transforming a stagnant, but rapidly growing market with a huge unmet patient need,” said Chambers. “The Tablo® Hemodialysis System has the potential to fundamentally change the way dialysis is delivered and improve the lives of patients and providers, while also driving significant cost efficiencies.”
Although more than 91 million dialysis treatments take place in the United States each year at an estimated annual cost of $65 billion, little meaningful technology or service model innovation has been introduced in decades. Tablo was specifically designed to reduce the cost and complexity of dialysis, while improving the experience for patients and providers. With real-time water purification and dialysis fluid production integrated in a single, compact system, Tablo functions like a dialysis clinic on wheels. Requiring just an electrical outlet and tap water to operate, Tablo frees providers from having to rely on expensive clinic infrastructure, enabling on-demand, cost-effective dialysis in a range of environments. Tablo was designed to look and feel like an intuitive consumer product, keeping end-user simplicity in mind. Wireless data, sensor-based automati
What is Rebecca Chambers' net worth?
The estimated net worth of Rebecca Chambers is at least $72,777.60 as of June 24th, 2021. Ms. Chambers owns 30,324 shares of Outset Medical stock worth more than $72,778 as of April 26th. This net worth approximation does not reflect any other investments that Ms. Chambers may own. Learn More about Rebecca Chambers' net worth.
How do I contact Rebecca Chambers?
Has Rebecca Chambers been buying or selling shares of Outset Medical?
Rebecca Chambers has not been actively trading shares of Outset Medical during the last quarter. Most recently, Rebecca Chambers sold 16,727 shares of the business's stock in a transaction on Thursday, June 24th. The shares were sold at an average price of $50.72, for a transaction totalling $848,393.44. Following the completion of the sale, the chief financial officer now directly owns 30,324 shares of the company's stock, valued at $1,538,033.28. Learn More on Rebecca Chambers' trading history.
Who are Outset Medical's active insiders?
Are insiders buying or selling shares of Outset Medical?
In the last year, insiders at the sold shares 34 times. They sold a total of 183,768 shares worth more than $2,821,339.29. The most recent insider tranaction occured on March, 15th when SVP Marc Nash sold 2,391 shares worth more than $5,092.83. Insiders at Outset Medical own 3.5% of the company.
Learn More about insider trades at Outset Medical. Information on this page was last updated on 3/15/2024.
